即時脂質檢測市場－全球產業規模、佔有率、趨勢、機會和預測（按產品、應用、疾病適應症、最終用戶、地區和競爭細分，2020 年至 2030 年）

2024 年全球即時血脂檢測市場規模為 7.3561 億美元，預計到 2030 年將達到 10.7248 億美元，複合年成長率為 6.46%。受心血管疾病發病率上升和早期血脂檢測日益重要的推動，該市場正在穩步擴張。即時血脂檢測 (POC) 可提供快速、準確的診斷，支援在初級保健和急診環境中及時做出臨床決策。人們的健康意識不斷增強以及對預防保健的重視加速了即時血脂檢測的普及，這種檢測因其易用性和診斷價值而受到醫生和患者的青睞。即時血脂檢測與行動診所和社區藥局的整合進一步提高了其可近性。具有藍牙和雲端功能的攜帶式血脂分析儀的進步也正在改變患者監測以及資料與電子健康記錄的整合方式。可同時檢測多種生物標記的多分析物平台的需求正在成長，這與向分散診斷和基於價值的醫療保健服務的轉變相輔相成。

關鍵市場促進因素

心血管疾病和血脂異常盛行率上升

主要市場挑戰

對準確性和可靠性的擔憂

主要市場趨勢

數位健康科技的整合

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球即時脂質測試市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按產品（儀器、耗材）
  • 依應用（高血脂、高三酸甘油脂血症、丹吉爾氏症、高脂蛋白血症、家族性高膽固醇血症、其他）
  • 依疾病適應症（脂質和脂蛋白疾病、動脈粥狀硬化、肝腎疾病、糖尿病、其他）
  • 按最終使用者（醫院、診所、研究和診斷實驗室等）
  • 按公司分類（2024）
  • 按地區
• 市場地圖

第6章：北美即時脂質檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第7章：歐洲即時脂質測試市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區即時脂質檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲

第9章：南美洲即時脂質檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲即時脂質測試市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如有）
• 最新動態

第13章：干擾：衝突、流行病與貿易壁壘

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

• Callegari Srl
• Sinocare Inc.
• Abbott Laboratories
• MiCoBio
• Nova Biomedical
• VivaChek Biotech (Hangzhou) Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• Menarini Group
• SD Biosensor, Inc.
• Becton, Dickinson and Company

第 16 章：策略建議

第17章調查會社について,免責事項

The Global Point of Care Lipid Test Market was valued at USD 735.61 Million in 2024 and is projected to reach USD 1072.48 Million by 2030, registering a CAGR of 6.46%. The market is expanding steadily, driven by the rising incidence of cardiovascular diseases and the growing importance of early lipid level detection. Point-of-care (POC) lipid testing offers rapid, accurate diagnostics, supporting timely clinical decisions in primary care and emergency settings. Increasing health awareness and emphasis on preventive care have accelerated the adoption of POC lipid tests, which are gaining popularity among both physicians and patients for their ease of use and diagnostic value. Their integration into mobile clinics and community pharmacies further enhances accessibility. Advancements in portable lipid analyzers with Bluetooth and cloud capabilities are also transforming patient monitoring and data integration with electronic health records. The demand for multi-analyte platforms that test for multiple biomarkers simultaneously is on the rise, complementing the shift toward decentralized diagnostics and value-based healthcare delivery.

Key Market Drivers

Rising Prevalence of Cardiovascular Diseases and Dyslipidemia

The increasing global burden of cardiovascular diseases (CVDs) and dyslipidemia is a primary driver of the Point of Care (POC) Lipid Test Market. Conditions such as coronary artery disease, hypertension, and stroke remain among the leading causes of death. Dyslipidemia, defined by abnormal cholesterol or triglyceride levels, is a major risk factor. In 2020, nearly 12% of U.S. adults had high total cholesterol, with over 38% displaying borderline or elevated levels. POC lipid testing allows for immediate results, enabling prompt therapeutic actions like prescribing statins or initiating lifestyle interventions. These tests are especially beneficial in primary care, outpatient clinics, and community screenings, helping improve patient compliance and supporting proactive cardiovascular risk management. Public health campaigns have also incorporated POC lipid testing, particularly in rural and underserved areas.

Key Market Challenges

Concerns Regarding Accuracy and Reliability

A notable challenge for the POC lipid test market is the ongoing concern over test accuracy and reliability compared to laboratory-based diagnostics. While the convenience and speed of POC tests are appealing, variability in calibration, operator handling, and environmental conditions can compromise test performance. These inconsistencies may lead to incorrect readings, influencing clinical decisions and potentially affecting patient safety. The diagnostic accuracy of some devices remains under scrutiny, particularly in uncontrolled environments, creating hesitation among clinicians and regulatory bodies. The lack of standardized manufacturing practices and rigorous quality validation also impacts market confidence. In lower-resource settings, insufficient training and infrastructure further limit the reliability of test outcomes. Addressing these concerns will require standardized quality benchmarks, broader training programs, and enhanced device design to match lab-grade diagnostic standards.

Key Market Trends

Integration of Digital Health Technologies

The market is undergoing a digital transformation as point-of-care lipid testing devices increasingly integrate with digital health technologies. These devices now feature real-time data transfer capabilities to electronic health records (EHRs), enhancing clinical decision-making and workflow efficiency. Cloud-based systems support centralized data storage, remote access, and predictive analytics, enabling proactive risk management. Smartphone-compatible devices and mobile health applications allow patients to track cholesterol levels, medication adherence, and lifestyle habits from home, fostering a more engaged and personalized approach to lipid management. Artificial intelligence (AI) and machine learning (ML) tools are also being introduced to interpret test data more accurately and identify complex risk patterns. These innovations align with value-based care strategies and are particularly valuable in supporting long-term disease prevention and management.

Key Market Players

• Callegari Srl
• Sinocare Inc.
• Abbott Laboratories
• MiCoBio
• Nova Biomedical
• VivaChek Biotech (Hangzhou) Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• Menarini Group
• SD Biosensor, Inc.
• Becton, Dickinson and Company

Report Scope

In this report, the Global Point of Care Lipid Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Point of Care Lipid Test Market, By Product:

• Instruments
• Consumables

Point of Care Lipid Test Market, By Application:

• Hyperlipidemia
• Hypertriglyceridemia
• Tangier Disease
• Hyperlipoproteinemia
• Familial Hypercholesterolemia
• Others

Point of Care Lipid Test Market, By Disease Indication:

• Lipid and Lipoprotein Disorders
• Atherosclerosis
• Liver and Renal Diseases
• Diabetes Mellitus
• Others

Point of Care Lipid Test Market, By End User:

• Hospitals
• Clinics
• Research and Diagnostic Laboratories
• Others

Point of Care Lipid Test Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Point of Care Lipid Test Market.

Available Customizations

Global Point of Care Lipid Test Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Point of Care Lipid Test Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Consumables)
  • 5.2.2. By Application (Hyperlipidemia, Hypertriglyceridemia, Tangier Disease, Hyperlipoproteinemia, Familial Hypercholesterolemia, Others)
  • 5.2.3. By Disease Indication (Lipid and Lipoprotein Disorders, Atherosclerosis, Liver and Renal Diseases, Diabetes Mellitus, Others)
  • 5.2.4. By End User (Hospitals, Clinics, Research and Diagnostic Laboratories, Others)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Point of Care Lipid Test Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Disease Indication
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Point of Care Lipid Test Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Disease Indication
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Point of Care Lipid Test Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Disease Indication
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Point of Care Lipid Test Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Disease Indication
      • 6.3.3.2.4. By End User

7. Europe Point of Care Lipid Test Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Disease Indication
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Point of Care Lipid Test Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Disease Indication
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Point of Care Lipid Test Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Disease Indication
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Point of Care Lipid Test Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Disease Indication
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Point of Care Lipid Test Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Disease Indication
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Point of Care Lipid Test Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Disease Indication
      • 7.3.5.2.4. By End User

8. Asia-Pacific Point of Care Lipid Test Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Disease Indication
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Point of Care Lipid Test Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Disease Indication
      • 8.3.1.2.4. By End User
  • 8.3.2. India Point of Care Lipid Test Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Disease Indication
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea Point of Care Lipid Test Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Disease Indication
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan Point of Care Lipid Test Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Disease Indication
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Point of Care Lipid Test Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Disease Indication
      • 8.3.5.2.4. By End User

9. South America Point of Care Lipid Test Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Disease Indication
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Point of Care Lipid Test Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Disease Indication
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Point of Care Lipid Test Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Disease Indication
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Point of Care Lipid Test Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Disease Indication
      • 9.3.3.2.4. By End User

10. Middle East and Africa Point of Care Lipid Test Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Disease Indication
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Point of Care Lipid Test Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Disease Indication
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Point of Care Lipid Test Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Disease Indication
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Point of Care Lipid Test Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Disease Indication
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Callegari Srl
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Sinocare Inc.
• 15.3. Abbott Laboratories
• 15.4. MiCoBio
• 15.5. Nova Biomedical
• 15.6. VivaChek Biotech (Hangzhou) Co., Ltd.
• 15.7. F. Hoffmann-La Roche Ltd.
• 15.8. Menarini Group
• 15.9. SD Biosensor, Inc.
• 15.10. Becton, Dickinson and Company

16. Strategic Recommendations

17. About Us & Disclaimer